Literature DB >> 28389867

Expression of the VP40 antigen from the Zaire ebolavirus in tobacco plants.

Elizabeth Monreal-Escalante1, Abel A Ramos-Vega2, Jorge A Salazar-González1, Bernardo Bañuelos-Hernández1, Carlos Angulo2, Sergio Rosales-Mendoza3.   

Abstract

MAIN
CONCLUSION: The plant cell is able to produce the VP40 antigen from the Zaire ebolavirus , retaining the antigenicity and the ability to induce immune responses in BALB/c mice. The recent Ebola outbreak evidenced the need for having vaccines approved for human use. Herein we report the expression of the VP40 antigen from the Ebola virus as an initial effort in the development of a plant-made vaccine that could offer the advantages of being cheap and scalable, which is proposed to overcome the rapid need for having vaccines to deal with future outbreaks. Tobacco plants were transformed by stable DNA integration into the nuclear genome using the CaMV35S promoter and a signal peptide to access the endoplasmic reticulum, reaching accumulation levels up to 2.6 µg g-1 FW leaf tissues. The antigenicity of the plant-made VP40 antigen was evidenced by Western blot and an initial immunogenicity assessment in test animals that revealed the induction of immune responses in BALB/c mice following three weekly oral or subcutaneous immunizations at very low doses (125 and 25 ng, respectively) without accessory adjuvants. Therefore, this plant-based vaccination prototype is proposed as an attractive platform for the production of vaccines in the fight against Ebola virus disease outbreaks.

Entities:  

Keywords:  Antigen delivery system; Ebola; Humoral response; Molecular pharming; Oral vaccine; Subunit vaccine

Mesh:

Substances:

Year:  2017        PMID: 28389867     DOI: 10.1007/s00425-017-2689-5

Source DB:  PubMed          Journal:  Planta        ISSN: 0032-0935            Impact factor:   4.116


  36 in total

1.  Quantitative real-time PCR assay for determining transgene copy number in transformed plants.

Authors:  D J Ingham; S Beer; S Money; G Hansen
Journal:  Biotechniques       Date:  2001-07       Impact factor: 1.993

Review 2.  Transgenic plants: a 5-year update on oral antipathogen vaccine development.

Authors:  Marisela Hernández; Gabriela Rosas; Jacquelynne Cervantes; Gladis Fragoso; Sergio Rosales-Mendoza; Edda Sciutto
Journal:  Expert Rev Vaccines       Date:  2014-08-27       Impact factor: 5.217

3.  Induction of humoral and CD8+ T cell responses are required for protection against lethal Ebola virus infection.

Authors:  Kelly L Warfield; Gene Olinger; Emily M Deal; Dana L Swenson; Michael Bailey; Diane L Negley; Mary Kate Hart; Sina Bavari
Journal:  J Immunol       Date:  2005-07-15       Impact factor: 5.422

4.  Ebola virus VP40 drives the formation of virus-like filamentous particles along with GP.

Authors:  Takeshi Noda; Hiroshi Sagara; Emiko Suzuki; Ayato Takada; Hiroshi Kida; Yoshihiro Kawaoka
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

Review 5.  Plant-based oral vaccines: results of human trials.

Authors:  C O Tacket
Journal:  Curr Top Microbiol Immunol       Date:  2009       Impact factor: 4.291

6.  Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge.

Authors:  Kelly L Warfield; Dana L Swenson; Gene G Olinger; Warren V Kalina; M Javad Aman; Sina Bavari
Journal:  J Infect Dis       Date:  2007-11-15       Impact factor: 5.226

7.  Genome-wide analysis of Agrobacterium T-DNA integration sites in the Arabidopsis genome generated under non-selective conditions.

Authors:  Sang-Ic Kim; Stanton B Gelvin
Journal:  Plant J       Date:  2007-06-30       Impact factor: 6.417

Review 8.  Plant glyco-biotechnology on the way to synthetic biology.

Authors:  Andreas Loos; Herta Steinkellner
Journal:  Front Plant Sci       Date:  2014-10-08       Impact factor: 5.753

9.  Characterization of the Ebola virus nucleoprotein-RNA complex.

Authors:  Takeshi Noda; Kyoji Hagiwara; Hiroshi Sagara; Yoshihiro Kawaoka
Journal:  J Gen Virol       Date:  2010-02-17       Impact factor: 3.891

10.  Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp.

Authors:  Xiangguo Qiu; Gary Wong; Jonathan Audet; Alexander Bello; Lisa Fernando; Judie B Alimonti; Hugues Fausther-Bovendo; Haiyan Wei; Jenna Aviles; Ernie Hiatt; Ashley Johnson; Josh Morton; Kelsi Swope; Ognian Bohorov; Natasha Bohorova; Charles Goodman; Do Kim; Michael H Pauly; Jesus Velasco; James Pettitt; Gene G Olinger; Kevin Whaley; Bianli Xu; James E Strong; Larry Zeitlin; Gary P Kobinger
Journal:  Nature       Date:  2014-08-29       Impact factor: 49.962

View more
  4 in total

Review 1.  Plant-made vaccines and reagents for the One Health initiative.

Authors:  Edward Peter Rybicki
Journal:  Hum Vaccin Immunother       Date:  2017-08-28       Impact factor: 3.452

2.  Characterization and Mapping of a Novel Premature Leaf Senescence Mutant in Common Tobacco (Nicotiana tabacum L.).

Authors:  Xiaoming Gao; Xinru Wu; Guanshan Liu; Zenglin Zhang; Jiangtao Chao; Zhiyuan Li; Yongfeng Guo; Yuhe Sun
Journal:  Plants (Basel)       Date:  2019-10-15

3.  Alfalfa Plants (Medicago sativa L.) Expressing the 85B (MAP1609c) Antigen of Mycobacterium avium subsp. paratuberculosis Elicit Long-Lasting Immunity in Mice.

Authors:  Elizabeth Monreal-Escalante; Cristhian Sández-Robledo; Amalia León-Gallo; Virginie Roupie; Kris Huygen; Sawako Hori-Oshima; Mario Arce-Montoya; Sergio Rosales-Mendoza; Carlos Angulo
Journal:  Mol Biotechnol       Date:  2021-03-02       Impact factor: 2.695

Review 4.  Advances in Designing and Developing Vaccines, Drugs, and Therapies to Counter Ebola Virus.

Authors:  Kuldeep Dhama; Kumaragurubaran Karthik; Rekha Khandia; Sandip Chakraborty; Ashok Munjal; Shyma K Latheef; Deepak Kumar; Muthannan Andavar Ramakrishnan; Yashpal Singh Malik; Rajendra Singh; Satya Veer Singh Malik; Raj Kumar Singh; Wanpen Chaicumpa
Journal:  Front Immunol       Date:  2018-08-10       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.